All Stories

  1. Novel scores relevant to antimicrobial resistance and hospital-acquired infections developed with data from a multi-hospital consortium in the Parisian region of France
  2. L’infection à Mycobacterium ulcerans ou ulcère de Buruli
  3. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study
  4. Corrigendum to “Pharmacokinetics/pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenation” [International Journal of Antimicrobial Agents Volume 61 (2023)106765]
  5. Pharmacokinetics/pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenation
  6. Active tuberculosis screening among the displaced population fleeing Ukraine, France, February to October 2022
  7. Rapid selection of a cefiderocol-resistantEscherichia coliproducing NDM-5 associated with a single amino acid substitution in the CirA siderophore receptor
  8. Impact de la première année de la pandémie de COVID-19 sur l’épidémiologie des infections invasives (bactériémies) dans les hôpitaux de l’Assistance Publique–Hôpitaux de Paris
  9. Antibiotic Stewardship in Treatment of Osteoarticular Infections Based on Local Epidemiology and Bacterial Growth Times
  10. Investigation of healthcare-associated COVID-19 in a large French hospital group by whole-genome sequencing
  11. Decrease of hospital- and community-acquired bloodstream infections due to Streptococcus pneumoniae and Streptococcus pyogenes during the first year of the COVID-19 pandemic: A time-series analysis in Paris region
  12. Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019
  13. Early-onset neonatal sepsis in the Paris area: a population-based surveillance study from 2019 to 2021
  14. Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France
  15. Decrease of carbapenemase‐producing Enterobacteriaceae incidence during the first year of the COVID‐19 pandemic
  16. Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment
  17. atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure
  18. Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020
  19. Clinical, epidemiological and therapeutic characteristics of Mycoplasma genitalium infection in a French STI center
  20. Surging bloodstream infections and antimicrobial resistance during the first wave of COVID–19: a study in a large multihospital institution in the Paris region
  21. Corynebacterium striatum thrombophlebitis: a nosocomial multidrug-resistant disease?
  22. A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples
  23. Clostridioides difficile Infection Rates after Ceftolozane–Tazobactam and Ceftazidime–Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study
  24. Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections
  25. Impact of stewardship strategy on antibiotic use in Clostridoides difficile infection
  26. Controlling healthcare-associated transmission of SARS-CoV-2 variant of concern 202012/01 in a large hospital network
  27. Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay
  28. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events
  29. Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis
  30. Impact of the revised definition of extensively drug-resistant tuberculosis
  31. Mycobacterium chimaera Genomics With Regard to Epidemiological and Clinical Investigations Conducted for an Open Chest Postsurgical Mycobacterium chimaera Infection Outbreak
  32. Efficacy of aztreonam with ß-lactamase inhibitors against metallo-carbapenemase-producing Enterobacteria
  33. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
  34. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study
  35. Do Contact Precautions Reduce the Incidence of Intensive Care Unit–Acquired Pseudomonas aeruginosa Infections? The DPCPYO (Detection and Contact Precautions for Patients With P. aeruginosa) Cluster-Randomized Crossover Trial
  36. Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety
  37. Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses
  38. Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema
  39. Usefulness of point-of-care multiplex PCR to rapidly identify pathogens responsible for ventilator-associated pneumonia and their resistance to antibiotics: an observational study
  40. Validation of the Bacterial Meningitis Score in adults consulting at an emergency department: a retrospective multicentric study
  41. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective
  42. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
  43. Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing
  44. Awareness among French healthcare workers of the transmission of multidrug resistant organisms: a large cross-sectional survey
  45. Q203 containing fully intermittent oral regimens exhibited high sterilizing activity against Mycobacterium ulcerans in mice
  46. Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium
  47. A nationwide survey on involvement of clinical microbiologists in antibiotic stewardship programmes in large French hospitals
  48. Erwinia billingiaeas Unusual Cause of Septic Arthritis, France, 2017
  49. Trends and prediction of antimicrobial susceptibility in urinary bacteria isolated in European emergency departments: the EuroUTI 2010-2016 Study
  50. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
  51. Molecular epidemiology of Pseudomonas aeruginosa isolated from infected ICU patients: a French multicenter 2012–2013 study
  52. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study
  53. Introduction – épidémiologie de la tuberculose et de l’infection tuberculeuse latente
  54. Recommandations pratiques pour l’utilisation et l’interprétation des tests de détection de l’interféron gamma dans le diagnostic de l’infection tuberculeuse latente et de la tuberculose maladie
  55. Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen
  56. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
  57. Trimethoprim susceptibility in E. coli community-acquired urinary tract infections in France
  58. Management and outcome of bloodstream infections: a prospective survey in 121 French hospitals (SPA-BACT survey)
  59. Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016
  60. Bacillus cereus, a serious cause of nosocomial infections: Epidemiologic and genetic survey
  61. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study
  62. Comparison of methods available for identification of Mycobacterium chimaera
  63. Surveillance for control of antimicrobial resistance
  64. Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015
  65. Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia
  66. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study
  67. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria
  68. Xe Congrès international de la Société de pathologie exotique, 8-9 novembre 2017, Haïphong (Vietnam) – Accès à la chirurgie en zones tropicales
  69. Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis
  70. Bacterial biofilm under flow: First a physical struggle to stay, then a matter of breathing
  71. Erratum to ‘Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae’ [International Journal of Antimicrobial Agents 49/1 67–73]
  72. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria
  73. Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosi s in France
  74. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries
  75. Multidrug and extensively drug-resistant tuberculosis
  76. Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory
  77. Application of guidelines for aminoglycosides use in French hospitals in 2013–2014
  78. Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis
  79. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors
  80. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
  81. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice
  82. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
  83. In vivo Mycobacterium tuberculosisfluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests
  84. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method
  85. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
  86. MYCOBACT-16 - Tolérance et efficacité d’un traitement prolongé avec bédaquiline dans la tuberculose multi résistante
  87. Performance of the New Version (v2.0) of the GenoType MTBDRslTest for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains
  88. Multidrug-resistant bacteria transmitted through high-density EEG in ICU
  89. Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis
  90. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013
  91. XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions
  92. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis
  93. qnrA6genetic environment and quinolone resistance conferred onProteus mirabilis
  94. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial
  95. Carbapenem use in French hospitals: A nationwide survey at the patient level
  96. Antibiotic use and good practice in 314 French hospitals: The 2010 SPA2 prevalence study
  97. Corrigendum to ‘Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams’ [Clin Microbiol Infec 21 (2015) 649.e1–649.e10]
  98. High Rate of Multidrug-Resistant Gram-Negative Bacilli Carriage and Infection in Hospitalized Returning Travelers: a Cross-Sectional Cohort Study
  99. Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex
  100. First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs
  101. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis
  102. Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams
  103. Bédaquiline : de l’in vitro aux essais cliniques d’un nouvel antituberculeux
  104. Detection of OXA-48-like carbapenemase genes by the Xpert® Carba-R test: room for improvement
  105. Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011
  106. Survey of French physician practices in treatment and control of transmission of smear-positive tuberculosis
  107. Registre électronique pour la prise en charge, le suivi et la surveillance des cas de tuberculose à bacilles multi-résistants en France
  108. « Groupe thérapeutique des infections à mycobactéries difficiles à traiter » et prise en charge des TB MDR : bilan 2005–2013
  109. Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis
  110. Molecular epidemiology of OXA-48-producing Klebsiella pneumoniae in France
  111. Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort
  112. Significant Difference in Drug Susceptibility Distribution between Mycobacterium avium and Mycobacterium intracellulare
  113. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis
  114. Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12
  115. K-06: Évaluation de nouveaux traitements oraux intermittents dans un modèle murin d’infection à Mycobacterium ulcerans
  116. Chirurgie et tuberculose multi/ultrarésistante : une revue de la littérature réhabilite une intervention adjuvante à l’antibiothérapie chez des patients sélectionnés
  117. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012
  118. Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility
  119. First report of the predominance of clonal complex 398 Staphylococcus aureus strains in osteomyelitis complicating diabetic foot ulcers: a national French study
  120. Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis
  121. Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990 to 2007
  122. Different Factors Associated with CTX-M-Producing ST131 and Non-ST131 Escherichia coli Clinical Isolates
  123. A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union
  124. Assessment of Organizational Measures to Prevent Nosocomial Tuberculosis in Health Facilities of 4 Sub-Saharan Countries in 2010
  125. Aerosolized Antibiotics for Ventilator-associated Pneumonia
  126. Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant Pseudomonas aeruginosa  and Acinetobacter baumannii 
  127. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
  128. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis
  129. Alliance contre les bactéries multirésistantes : sauvons les antibiotiques !
  130. Link Between Carbapenemase‐ProducingEnterobacteriaCarriage and Cross‐Border Exchanges: Eight‐Year Surveillance in a Large French Multihospitals Institution
  131. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
  132. Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France
  133. Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris
  134. Distinguishing Colonization From Infection With Staphylococcus aureus in Diabetic Foot Ulcers With Miniaturized Oligonucleotide Arrays: A French multicenter study
  135. Patient's Origin and Lifestyle Associated with CTX-M-Producing Escherichia coli: A Case-Control-Control Study
  136. Point prevalence survey of antibiotic use in French hospitals in 2009
  137. Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE)
  138. Multidrug‐ResistantAcinetobacter baumanniiInfections in Three Returning Travelers Evacuated From Algeria, Thailand, and Turkey After Hospitalization in Local Intensive Care Units
  139. Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused byPseudomonas aeruginosa
  140. Halte à la résistance : sauvons les antibiotiques
  141. Low carriage of vancomycin-resistant enterococci in the digestive tract of French hospitalised patients: a nationwide prospective study in 2006
  142. Comparison of Nine Phenotypic Methods for Detection of Extended-Spectrum  -Lactamase Production by Enterobacteriaceae
  143. Panton-Valentine Leukocidin-Positive and Toxic Shock Syndrome Toxin 1-Positive Methicillin-ResistantStaphylococcus aureus: a French Multicenter Prospective Study in 2008
  144. Résistance aux antituberculeux et impasse thérapeutique
  145. Nationwide Investigation of Extended-Spectrum β-Lactamases, Metallo-β-Lactamases, and Extended-Spectrum Oxacillinases Produced by Ceftazidime-Resistant Pseudomonas aeruginosa Strains in France
  146. Curbing Methicillin-Resistant Staphylococcus aureus in 38 French Hospitals Through a 15-Year Institutional Control Program
  147. Effect of Catheter-Lock Solutions on Catheter-Related Infection and Inflammatory Syndrome in Hemodialysis Patients: Heparin versus Citrate 46% versus Heparin/Gentamicin
  148. Rapid Curbing of a Vancomycin-ResistantEnterococcus faeciumOutbreak in a Nephrology Department
  149. Carriage of Methicillin-Resistant Staphylococcus aureus in Home Care Settings
  150. Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice
  151. Nationwide survey of extended-spectrum β-lactamase-producing Enterobacteriaceae in the French community setting
  152. Systematic Microbiological Tests in Kidney Transplantation and Their Value in Predicting Posttransplantation Infection
  153. Increase in hospital-acquired bloodstream infections caused by extended spectrum β-lactamase-producing Escherichia coli in a large French teaching hospital
  154. La résistance aux antituberculeux en France à travers les données des réseaux Azay-Mycobactéries et du Centre National de Référence des Mycobactéries
  155. Entérocoques résistants à la vancomycine : données des réseaux de l’ONERBA et résultats de l’enquête nationale trans-réseaux 2006 sur le portage digestif
  156. Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice
  157. Extended-spectrum β-lactamases in long-term-care facilities
  158. Evaluation of data quality in a laboratory-based surveillance of M. tuberculosis drug resistance and impact on the prevalence of resistance: France, 2004
  159. A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995 2004
  160. Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice
  161. Preemptive Isolation to Prevent Methicillin-Resistant Staphylococcus aureus Cross-Transmission in Diabetic Foot
  162. Conduite à tenir devant un malade porteur d'un entérocoque résistant à la vancomycine
  163. An intervention programme for the management of multidrug-resistant tuberculosis in France
  164. Type II topoisomerase mutations in clinical isolates of Enterobacter cloacae and other enterobacterial species harbouring the qnrA gene
  165. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients*
  166. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis
  167. Activité de l’ertapénème et d’autres antibiotiques sur les bacilles aérobies à Gram négatif isolés d’infections respiratoires et abdominales d’origine communautaire en France 2003
  168. An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001–2002
  169. Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin
  170. Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002–2005
  171. Gentamicin-Susceptible or Gentamicin-Resistant Methicillin-ResistantStaphylococcus aureusA Case-Case Study
  172. In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans
  173. Implementation of isolation precautions: role of a targeted information flyer
  174. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983–2002
  175. Modification des caractéristiques épidémiologiques de la tuberculose multirésistante en France en 2002-2003
  176. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease
  177. Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a French university hospital
  178. Résistance aux antituberculeux
  179. Methicillin-resistant Staphylococcus aureus producing Panton–Valentine leukocidin in a retrospective case series from 12 French hospital laboratories, 2000–2003
  180. Résistance aux antibiotiques : des Chiffres de l'ONERBA au Bon Usage
  181. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains
  182. Nosocomial infections and hospital mortality: a multicentre epidemiological study
  183. A-04 Incidence et caractéristiques de la méningite tuberculeuse en France en 2000
  184. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact
  185. Preventing Central Venous Catheter-Associated Primary Bloodstream Infections: Characteristics of Practices Among Hospitals Participating in the Evaluation of Processes and Indicators in Infection Control (EPIC) Study
  186. Multidrug-resistant tuberculosis: eight years of surveillance in France
  187. Comparison of US and non-US central venous catheter infection rates: Evaluation of processes and indicators in infection control study
  188. La multirésistance (MDR) de Mycobacterium tuberculosis aux antibiotiques en France depuis 1992
  189. Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice
  190. Sixty-three Cases of Mycobacterium marinum Infection
  191. Recommandations des experts de la Société de réanimation de langue française, janvier 2002Prévention de la transmission croisée en réanimation
  192. Isolement respiratoire chez l’adulte de réanimation
  193. Lung Tissue Concentrations of Nebulized Amikacin during Mechanical Ventilation in Piglets with Healthy Lungs
  194. Évolution de la sensibilité aux quinolones et aux fluoroquinolones des bacilles à Gram négatif aérobies isolés dans un hôpital universitaire (1992–2000)
  195. Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice
  196. Efficacies of Clarithromycin Regimens against Mycobacterium xenopi in Mice
  197. Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98
  198. Outcomes of Primary and Catheter-related Bacteremia
  199. Global Trends in Resistance to Antituberculosis Drugs
  200. Impact of Hospital Care on Incidence of Bloodstream Infection: The Evaluation of Processes and Indicators in Infection Control Study
  201. Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice
  202. The Influence of the Composition of the Nursing Staff on Primary Bloodstream Infection Rates in a Surgical Intensive Care Unit
  203. Outcome of Multi-drug-resistant Tuberculosis in France
  204. Type II Topoisomerase Mutations in Ciprofloxacin-Resistant Strains of Pseudomonas aeruginosa
  205. Pacemaker Endocarditis Due to Candida albicans: Case Report and Review
  206. Pharmacodynamics of antibiotics in fibrin clots
  207. Reexpansion Pulmonary Edema Localized to a Lobe